T1000	Negation 766 768	No
E1000	Negation:T1000 Scope:T1001
T1001	Span 766 805	No significative changes in EBV latency
T1002	Negation 678 688	Percentage
E1001	Negation:T1002 Scope:T1003
T1003	Span 678 707	Percentage of apoptotic cells
T1004	Negation 1045 1049	This
E1002	Negation:T1004 Scope:T1005
T1005	Span 1045 1139	This correlated with a strong reduction of BrdU incorporation after 24 h of TNFalpha treatment
T1006	Negation 806 809	nor
E1003	Negation:T1006 Scope:T1007
T1007	Span 806 853	nor in cell surface marker expression was found
T1008	Speculation 1249 1256	suggest
E1004	Speculation:T1008 Scope:T1009
T1009	Span 1249 1342	suggest that the TNFalpha gene could be one of the targets of NF-kappaB in EBV infected cells
T1010	Negation 1141 1143	No
E1005	Negation:T1010 Scope:T1011
T1011	Span 1141 1235	No effect was seen with non transfected cells or with cells transfected with a control plasmid
T1012	Speculation 1432 1435	may
E1006	Speculation:T1012 Scope:T1013
T1013	Span 1432 1484	may favour the proliferative effect of this cytokine
T1014	Speculation 1280 1285	could
E1007	Speculation:T1014 Scope:T1015
T1015	Span 1280 1484	could be one of the targets of NF-kappaB in EBV infected cells and that NF-kappaB protects EBV-infected cells from apoptosis induced by TNFalpha, which may favour the proliferative effect of this cytokine
